



Interventions that may improve the immune response to vaccination

If vaccination is imminent within days:

- Avoid acute stressors
- Obtain adequate sleep
- Avoid anti-inflammatory agents 2 days pre- and post
- If active infection, postpone vaccination

For all others, consider clinical recommendations below:

Public Health Measures:

- Masks
- Distancing
- Hand washing

Address Lifestyle Factors:

- Sleep
- Exercise
- Nutrition
- Stress
- Relationships
- Gut health (IFM's "DIGIN" and "5R")

Additional Considerations:

- **Address Comorbidities (CDC List)**
- Enhance immune function
- Address inflammation
- Smoking cessation
- Weight loss
- Mind/body therapies
- Dietary fiber
- Optimize microbiota
- Address autoimmunity
- Address hormonal balance

Options to Improve Physiological Function:

- Curcumin
- Resveratrol
- Quercetin
- Melatonin
- *Green tea extract
- *Glutathione or *N-acetylcysteine
- *Andrographis
- *Berberine

*For conditions below, consider agents above:

- Hypertension
- Diabetes
- CVD
- Hypertriglyceridemia
- Hyperinsulinemia
- Autoimmunity
- Obesity

Options to Support Immune Function:

- Vitamins A, C, D, E, B6, B12, Folate, Fe, Zn, Cu, Se
- Mushrooms
- Beta glucans
- Echinacea
- Quercetin
- Resveratrol

This document is a general guidance to practicing clinicians, may change with time, and it is not intended to supersede the medical judgment of the clinician. Please check with info@ifm.org for updates to the protocol. For copyright permission please contact permissions@ifm.org

References

Address Lifestyle Factors

1. Madison AA, Shrout MR, Renna ME, Kiecolt-Glaser JK. Psychological and behavioral predictors of vaccine efficacy: considerations for COVID-19. *Perspect Psychol Sci.* 2021;16(2):191–203. doi:10.1177/1745691621989243.
2. Prather AA, Hall M, Fury JM, et al. Sleep and antibody response to hepatitis B vaccination. *Sleep.* 2012;35(8):1063–1069. Published 2012 Aug 1. doi:10.5665/sleep.1990.
3. Keylock KT, Lowder T, Leifheit KA, et al. Higher antibody, but not cell-mediated, responses to vaccination in high physically fit elderly. *J Appl Physiol (1985).* 2007;102(3):1090–1098. doi:10.1152/japplphysiol.00790.2006.
4. Castrucci MR. Factors affecting immune responses to the influenza vaccine. *Hum Vaccin Immunother.* 2018;14(3):637–646. doi:10.1080/21645515.2017.1338547.
5. Butler MJ, Barrientos RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. *Brain Behav Immun.* 2020;87:53–54. doi:10.1016/j.bbi.2020.04.040.
6. Kiecolt-Glaser JK, Glaser R, Gravenstein S, Malarkey WB, Sheridan J. Chronic stress alters the immune response to influenza virus vaccine in older adults. *Proc Natl Acad Sci USA.* 1996;93(7):3043–3047. doi:10.1073/pnas.93.7.3043.
7. Miller GE, Cohen S, Pressman S, Barkin A, Rabin BS, Treanor JJ. Psychological stress and antibody response to influenza vaccination: when is the critical period for stress, and how does it get inside the body?. *Psychosom Med.* 2004;66(2):215–223. doi:10.1097/01.psy.0000116718.54414.9e.
8. Glaser R, Sheridan J, Malarkey WB, MacCallum RC, Kiecolt-Glaser JK. Chronic stress modulates the immune response to a pneumococcal pneumonia vaccine. *Psychosom Med.* 2000;62(6):804–807. doi:10.1097/00006842-200011000-00.
9. Pressman SD, Cohen S, Miller GE, Barkin A, Rabin BS, Treanor JJ. Loneliness, social network size, and immune response to influenza vaccination in college freshmen [published correction appears in Health Psychol. 2005 Jul;24(4):348]. *Health Psychol.* 2005;24(3):297–306. doi:10.1037/0278-6133.24.3.297.
10. Cianci R, Franzia L, Massaro MG, Borriello R, DeVito F, Gambassi G. The interplay between immunosenescence and microbiota in the efficacy of vaccines. *Vaccines (Basel).* 2020;8(4):636. Published 2020 Nov 2. doi:10.3390/vaccines8040636.
11. Lynn DJ, Pulendran B. The potential of the microbiota to influence vaccine responses. *J Leukoc Biol.* 2018;103(2):225–231. doi:10.1189/jlb.5MR0617-216R.

Options to Improve Physiological Function

12. Tozsér J, Benko S. Natural compounds as regulators of NLRP3 inflammasome-mediated IL-1 β production. *Mediators Inflamm.* 2016;2016:5460302. doi:10.1155/2016/5460302.
13. Khaerunnisa, S, Kurniawan, H; Awaluddin, R; Suhartati, S; Soetjipto, S. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. *Preprints* 2020, 2020030226. doi: 10.20944/preprints202003.0226.v1.
14. Yin H, Guo Q, Li X, et al. Curcumin suppresses IL-1 β secretion and prevents inflammation through inhibition of the NLRP3 inflammasome. *J Immunol.* 2018;200(8):2835–2846. doi:10.4049/jimmunol.1701495.
15. Gong Z, Zhao S, Zhou J, et al. Curcumin alleviates DSS-induced colitis via inhibiting NLRP3 inflammasome activation and IL-1 β production. *Mol Immunol.* 2018;104:11–19. doi:10.1016/j.molimm.2018.09.004.
16. Zhao J, Wang J, Zhou M, Li M, Li M, Tan H. Curcumin attenuates murine lupus via inhibiting NLRP3 inflammasome. *Int Immunopharmacol.* 2019;69:213–216. doi:10.1016/j.intimp.2019.01.046.
17. Kunnumakkara AB, Bordoloi D, Padmavathi G, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. *Br J Pharmacol.* 2017;174(11):1325–1348. doi:10.1111/bph.13621.
18. Brisdelli F, D'Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. *Curr Drug Metab.* 2009;10(6):530–546. doi:10.2174/138920009789375423.
19. Lin SC, Ho CT, Chuo WH, Li S, Wang TT, Lin CC. Effective inhibition of MERS-CoV infection by resveratrol. *BMC Infect Dis.* 2017;17(1):144. doi:10.1186/s12879-017-2253-8.
20. Dostal Z, Modriansky M. The effect of quercetin on microRNA expression: a critical review. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2019;163(2):95–106. doi:10.5507/bp.2019.030.
21. Wu W, Li R, Li X, et al. Quercetin as an antiviral agent inhibits influenza A virus (IAV) entry. *Viruses.* 2015;8(1):6. doi:10.3390/v8010006.
22. Kinker B, Comstock AT, Sajjan US. Quercetin: a promising treatment for the common cold. *J Anc Dis Prev Rem.* 2014;2:2:1000111. doi:10.4172/2329-8731.1000111.
23. Somerville VS, Braakhuis AJ, Hopkins WG. Effect of flavonoids on upper respiratory tract infections and immune function: a systematic review and meta-analysis. *Adv Nutr.* 2016;7(3):488–497. doi:10.3945/an.115.010538.
24. Qiu X, Kroeker A, He S, et al. Prophylactic efficacy of quercetin 3-?-O-D-glucoside against Ebola virus infection. *Antimicrob Agents Chemother.* 2016;60(9):5182–5188. doi:10.1128/AAC.00307-16.
25. Wong G, He S, Siragam V, et al. Antiviral activity of quercetin-3-?-O-D-glucoside against Zika virus infection. *Virol Sin.* 2017;32(6):545–547. doi:10.1007/s12250-017-4057-9.
26. Yi YS. Regulatory roles of flavonoids on inflammasome activation during inflammatory responses. *Mol Nutr Food Res.* 2018;62(13):e1800147. doi:10.1002/mnfr.201800147.
27. Favero G, Franceschetti L, Bonomini F, Rodella LF, Rezzani R. Melatonin as an anti-inflammatory agent modulating inflammasome activation. *Int J Endocrinol.* 2017;2017:1835195. doi:10.1155/2017/1835195.
28. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discov.* 2020;6:14. doi:10.1038/s41421-020-0153-3.
29. Zhang R, Wang X, Ni L, et al. COVID-19: melatonin as a potential adjuvant treatment. *Life Sci.* 2020;250:117583. doi:10.1016/j.lfs.2020.117583.

Options to Improve Physiological Function (cont.)

30. Adem S, Eyupoglu V, Sarfraz I, Rasul A, Ali M. Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: an in silico strategy unveils a hope against CORONA. *Preprints*. 2020;2020030333. doi:10.20944/preprints202003.0333.v1.
31. Matsumoto K, Yamada H, Takuma N, Niino H, Sagesaka YM. Effects of green tea catechins and theanine on preventing influenza infection among healthcare workers: a randomized controlled trial. *BMC Complement Altern Med*. 2011;11:15. doi:10.1186/1472-6882-11-15.
32. Lee HE, Yang G, Park YB, et al. Epigallocatechin-3-gallate prevents acute gout by suppressing NLRP3 inflammasome activation and mitochondrial DNA synthesis. *Molecules*. 2019;24(11):2138. doi:10.3390/molecules24112138.
33. McCarty MF, DiNicolantonio JJ. Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus. *Prog Cardiovasc Dis*. 2020;63(3):383-385. doi:10.1016/j.pcad.2020.02.007.
34. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. *Eur Respir J*. 1997;10(7):1535-1541. doi:10.1183/09031936.97.10071535.
35. Kligler B, Ulbricht C, Basch E, et al. Andrographis paniculata for the treatment of upper respiratory infection: a systematic review by the Natural Standard Research Collaboration. *Explore (NY)*. 2006;2(1):25-29. doi:10.1016/j.explore.2005.08.008.
36. Hu XY, Wu RH, Logue M, et al. Andrographis paniculata (Chuan Xin Lián) for symptomatic relief of acute respiratory tract infections in adults and children: a systematic review and meta-analysis. *PLoS One*. 2017;12(8):e0181780. doi:1371/journal.pone.0181780.
37. Gupta S, Mishra KP, Ganju L. Broad-spectrum antiviral properties of andrographolide. *Arch Virol*. 2017;162(3):611-623. doi:1007/s00705-016-3166-3.
38. Mussard E, Cesaro A, Lespessailles E, Legrain B, Bertaina-Raboin S, Toumi H. Andrographolide, a natural antioxidant: an update. *Antioxidants (Basel)*. 2019;8(12):E571. doi:3390/antiox8120571.
39. Varghese FS, Thaa B, Amrun SN, et al. The antiviral alkaloid berberine reduces chikungunya virus-induced mitogen-activated protein kinase signaling. *J Virol*. 2016;90(21):9743-9757. doi:1128/JVI.01382-16.
40. Varghese FS, Kaukinen P, Gläsker S, et al. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. *Antiviral Res*. 2016;126:117-124. doi:1016/j.antiviral.2015.12.012.
41. Shin HB, Choi MS, Yi CM, Lee J, Kim NJ, Inn KS. Inhibition of respiratory syncytial virus replication and virus-induced p38 kinase activity by berberine. *Int Immunopharmacol*. 2015;27(1):65-68. doi:1016/j.intimp.2015.04.045.
42. Dai Q, Zhang D, Yu H, et al. Berberine restricts coxsackievirus B type 3 replication via inhibition of c-Jun N-terminal kinase (JNK) and p38 MAPK activation in vitro. *Med Sci Monit*. 2017;23:1448-1455. doi:12659/msm.899804.
43. Wang YX, Yang L, Wang HQ, et al. Synthesis and evolution of berberine derivatives as a new class of antiviral agents against enterovirus 71 through the MEK/ERK pathway and autophagy. *Molecules*. 2018;23(8):E2084. doi:3390/molecules23082084.

Options to Support Immune Function

44. Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of vitamin A in the immune system. *J Clin Med*. 2018;7(9):258. doi:10.3390/jcm7090258.
45. Cui D, Moldoveanu Z, Stephensen CB. High-level dietary vitamin A enhances T-helper type 2 cytokine production and secretory immunoglobulin A response to influenza A virus infection in BALB/c mice. *J Nutr*. 2000;130(5):1132-1139. doi:10.1093/jn/130.5.1132.
46. Penkert RR, Rowe HM, Surman SL, Sealy RE, Rosch J, Hurwitz JL. Influences of vitamin A on vaccine immunogenicity and efficacy. *Front Immunol*. 2019;10:1576. Published 2019 Jul 17. doi:10.3389/fimmu.2019.01576.
47. Carr AC, Maggini S. Vitamin C and Immune Function. *Nutrients*. 2017;9(11):1211. doi:10.3390/nu9111211.
48. Zabet MH, Mohammadi M, Ramezani M, Khalili H. Effect of high-dose ascorbic acid on vasopressor's requirement in septic shock. *J Res Pharm Pract*. 2016;5(2):94-100. doi:10.4103/2279-042X.179569.
49. Schloss J, Lauche R, Harnett J, et al. Efficacy and safety of vitamin C in the management of acute respiratory infection and disease: a rapid review. *Adv Integr Med*. 2020;7(4):187-191. doi:10.1016/j.aimed.2020.07.008.
50. Vorilhon P, Arpjou B, Vaillant Roussel H, Merlin É, Pereira B, Cabaillet A. Efficacy of vitamin C for the prevention and treatment of upper respiratory tract infection. A meta-analysis in children. *Eur J Clin Pharmacol*. 2019;75(3):303-311. doi:10.1007/s00228-018-2601-7.
51. Sadarangani SP, Whitaker JA, Poland GA. "Let there be light": the role of vitamin D in the immune response to vaccines. *Expert Rev Vaccines*. 2015;14(11):1427-1440. doi:10.1586/14760584.2015.1082426.
52. Jolliffe DA, Camargo CA Jr, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. *Lancet Diabetes Endocrinol*. 2021;9(5):276-292. doi:10.1016/S2213-8587(21)00051-6.
53. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ*. 2017;356:i6583. Published 2017 Feb 15. doi:10.1136/bmj.i6583.
54. Fitch N, Becker AB, HayGlass KT. Vitamin D [1,25(OH)2D3] differentially regulates human innate cytokine responses to bacterial versus viral pattern recognition receptor stimuli. *J Immunol*. 2016;196(7):2965-2972. doi:10.4049/jimmunol.1500460.
55. Zdrengeha MT, Makrinioti H, Bagacean C, Bush A, Johnston SL, Stanciu LA. Vitamin D modulation of innate immune responses to respiratory viral infections. *Rev Med Virol*. 2017;27(1). doi:10.1002/rmv.1909.
56. Wouters-Wesseling W, Rozendaal M, Snijder M, et al. Effect of a complete nutritional supplement on antibody response to influenza vaccine in elderly people. *J Gerontol A Biol Sci Med Sci*. 2002;57(9):M563-M566. doi:10.1093/gerona/57.9.m563.
57. Allsup SJ, Shenkin A, Gosney MA, et al. Can a short period of micronutrient supplementation in older institutionalized people improve response to influenza vaccine? A randomized, controlled trial. *J Am Geriatr Soc*. 2004;52(1):20-24. doi:10.1111/j.1532-5415.2004.52005.x.
58. Gaullier JM, Sleboda J, Ofjord ES, et al. Supplementation with a soluble β -glucan exported from Shiitake medicinal mushroom, *Lentinus edodes* (Berk.) singer mycelium: a crossover, placebo-controlled study in healthy elderly. *Int J Med Mushrooms*. 2011;13(4):319-326. doi:10.1615/intjmedmushr.v13.i4.10.
59. Dai X, Stanilka JM, Rowe CA, et al. Consuming *Lentinula edodes* (Shiitake) mushrooms daily improves human immunity: a randomized dietary intervention in healthy young adults. *J Am Coll Nutr*. 2015;34(6):478-487. doi:1080/07315724.2014.950391.

Options to Support Immune Function (cont.)

60. Kodama N, Komuta K, Nanba H. Effect of Maitake (*Grifola frondosa*) D-fraction on the activation of NK cells in cancer patients. *J Med Food*. 2003;6(4):371-377. doi:1089/109662003772519949.
61. Jin X, Ruiz Beguerie J, Sze DM, Chan GC. *Ganoderma lucidum* (Reishi mushroom) for cancer treatment. *Cochrane Database Syst Rev*. 2012;(6):CD007731. doi:1002/14651858.CD007731.pub2.
62. Castro E, Calder PC, Roche HM. ?-1,3/1,6-glucans and immunity: state of the art and future directions. *Mol Nutr Food Res*. Published online March 29, 2020. doi:1002/mnfr.201901071.
63. Vetvicka V, Vannucci L, Sima P, Richter J. Beta glucan: supplement or drug? From laboratory to clinical trials. *Molecules*. 2019;24(7):E1251. doi:3390/molecules24071251.
64. Dharsono T, Rudnicka K, Wilhelm M, Schoen C. Effects of yeast (1,3)-(1,6)-beta-glucan on severity of upper respiratory tract infections: a double-blind, randomized, placebo-controlled study in healthy subjects. *J Am Coll Nutr*. 2019;38(1):40-50. doi:10.1080/07315724.2018.1478339.
65. Fuller R, Moore MV, Lewith G, et al. Yeast-derived B-1,3/1,6 glucan, upper respiratory tract infection and innate immunity in older adults. *Nutrition*. 2017;39-40:30-35. doi:1016/j.nut.2017.03.003.
66. Gan XH, Zhang L, Heber D, Bonavida B. Mechanism of activation of human peripheral blood NK cells at the single cell level by echinacea water soluble extracts: recruitment of lymphocyte-target conjugates and killer cells and activation of programming for lysis. *Int Immunopharmacol*. 2003;3(6):811-824. doi:1016/S1567-5769(02)00298-9.
67. Woelkart K, Marth E, Suter A, et al. Bioavailability and pharmacokinetics of Echinacea purpurea preparations and their interaction with the immune system. *Int J Clin Pharmacol Ther*. 2006;44(9):401-408. doi:5414/cpp44401.
68. Shah SA, Sander S, White CM, Rinaldi M, Coleman CI. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. *Lancet Infect Dis*. 2007;7(7):473-480. doi:1016/S1473-3099(07)70160-3.
69. Schoop R, Klein P, Suter A, Johnston SL. Echinacea in the prevention of induced rhinovirus colds: a meta-analysis. *Clin Ther*. 2006;28(2):174-183. doi:1016/j.clinthera.2006.02.001.
70. Linde K, Barrett B, Wölkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. *Cochrane Database Syst Rev*. 2006;(1):CD000530. doi:1002/14651858.CD000530.pub2.
71. Jawad M, Schoop R, Suter A, Klein P, Eccles R. Safety and efficacy profile of Echinacea purpurea to prevent common cold episodes: a randomized, double-blind, placebo-controlled trial. *Evid Based Complement Alternat Med*. 2012;2012:841315. doi:1155/2012/841315.